Effect of modified wuzi yanzong granule on patients with mild cognitive impairment from oxidative damage aspect.
OBJECTIVE
To observe the effects of modified Wuzi Yanzong Granule (WYG) on memory function and the activity of serum superoxide dismutase (SOD), malondialdehyde (MDA) levels, leukocyte mitochondrial DNA (mtDNA) deletion rate and beta-amyloid protein(1-28) (A beta(1-28)) in patients with mild cognitive impairment (MCI).


METHODS
Thirty-six patients with MCI were selected based on the internationally recognized Petersen's criteria, and equally and randomly assigned to two groups. The treated group was treated with WYG and the control group was treated with placebo for 3 months. In addition, 20 healthy subjects were included in the study as the normal control group. Changes of memory function, SOD activity, MDA content, leukocyte mtDNA deletion rate and A beta(1-28) content were observed before and after treatment.


RESULTS
Compared with the normal control group, the memory quotient and SOD activity in patients with MCI decreased significantly (P < 0.01), while MDA, A beta(1-28) levels and the leukocyte mtDNA deletion rate increased significantly (P < 0.01). After treatment, levels of memory quotient and serum SOD activity increased while the serum MDA level, leukocyte mtDNA deletion rate and A beta(1-28) level decreased in the treated group compared with those before treatment (P<0.01, P<0.05). Meanwhile, leukocyte mtDNA deletion rate and A beta(1-28) content in the treated group were all lower than those in the control group (P<0.05).


CONCLUSIONS
WYG could improve memory function in patients with MCI and the therapeutic mechanism is possibly related to the increased activity of anti-oxidase, the improved free radical metabolism and the alleviation of leukocyte mtDNA oxidation damage. WYG shows clinical significance in delaying the progression of MCI.
Wang
Xue-mei
XM
Department of Integrated Chinese and Western Medicine of Peking University First Hospital, Beijing, 100034, China. wangxuemei64@sohu.com
Fu
Hong
H
Liu
Geng-xin
GX
Zhu
Wei
W
Li
Li
L
Yang
Jin-xia
JX
D000368:Aged; D000369:Aged, 80 and over; D016229:Amyloid beta-Peptides / Q000097:blood; D003072:Cognition Disorders / Q000097:blood / Q000188:drug therapy* / Q000209:etiology / Q000473:pathology; D004272:DNA, Mitochondrial / Q000235:genetics; D018450:Disease Progression; D004311:Double-Blind Method; D004339:Drug Compounding; D004365:Drugs, Chinese Herbal / Q000008:administration & dosage*; D005260:Female; D006801:Humans; D008297:Male; D008315:Malondialdehyde / Q000097:blood; D008568:Memory / Q000187:drug effects; D008875:Middle Aged; D018384:Oxidative Stress / Q000502:physiology*; D010446:Peptide Fragments / Q000097:blood; D008517:Phytotherapy; D010919:Placebos; D013482:Superoxide Dismutase / Q000097:blood
D016229:Amyloid beta-Peptides; D004272:DNA, Mitochondrial; D004365:Drugs, Chinese Herbal; D010446:Peptide Fragments; D010919:Placebos; C084358:amyloid beta-protein (1-28); D008315:Malondialdehyde; D013482:Superoxide Dismutase